These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18555899)

  • 21. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rare diseases, definitions and epidemiology].
    Donnart A; Viollet V; Roinet-Tournay M
    Soins Pediatr Pueric; 2013; (274):14-6. PubMed ID: 24228328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 24. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Med Sci (Paris); 2016 Apr; 32 Spec No 1():29-33. PubMed ID: 27137859
    [No Abstract]   [Full Text] [Related]  

  • 26. [GPs: patients require you to doubt! Interview by Catherine Holué].
    Viollet V
    Rev Prat; 2012 Jan; 62(1):85-6. PubMed ID: 22335075
    [No Abstract]   [Full Text] [Related]  

  • 27. R&D policy, agency costs and innovation in personalized medicine.
    Yin W
    J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 29. [Presenting a research project on rare diseases to industrial companies].
    Ferry A
    Presse Med; 2012 May; 41 Suppl 1():S38-9. PubMed ID: 22483767
    [No Abstract]   [Full Text] [Related]  

  • 30. [The national plan for orphan rare diseases: nearly 10 years on].
    Guillevin L
    Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S9-11. PubMed ID: 23452775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare or orphan diseases -- a useful political concept.
    Baxter P
    Dev Med Child Neurol; 2012 Jul; 54(7):579. PubMed ID: 22607366
    [No Abstract]   [Full Text] [Related]  

  • 33. Commissioning for rare diseases: view from the frontline.
    Burls A; Austin D; Moore D
    BMJ; 2005 Oct; 331(7523):1019-21. PubMed ID: 16254306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Orphan drugs: problem of public health and economic stakes].
    Brandissou S; Yagoubi N; Hasselot N
    Therapie; 1996; 51(6):647-53. PubMed ID: 9164001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current views on rare diseases research and orphan drugs development].
    Jiang J; Li J; Liu W
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):724-9. PubMed ID: 21845839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 37. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rare pulmonary diseases: from the adoption of orphan diseases to structured healthcare networks].
    Cottin V; Cordier JF
    Rev Mal Respir; 2014 Dec; 31(10):889-92. PubMed ID: 25465349
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rare diseases in pulmonary medicine and its challenges].
    Wencker M; Teschler H; Vogelmeier C; Koczulla R
    Pneumologie; 2012 Jul; 66(7):437-41. PubMed ID: 22692970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.